| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7683051 | WYETH PHARMS | Crystalline polymorph of bazedoxifene acetate |
Mar, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6479535 | WYETH PHARMS | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
May, 2024
(7 months from now) | |
Duavee is owned by Wyeth Pharms.
Duavee contains Bazedoxifene Acetate; Estrogens, Conjugated.
Duavee has a total of 2 drug patents out of which 0 drug patents have expired.
Duavee was authorised for market use on 03 October, 2013.
Duavee is available in tablet;oral dosage forms.
Duavee can be used as prevention of postmenopausal osteoporosis; treatment of moderate to severe vasomotor symptoms associated with menopause.
The generics of Duavee are possible to be released after 10 March, 2027.
Drugs and Companies using BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED ingredient
Market Authorisation Date: 03 October, 2013
Treatment: Prevention of postmenopausal osteoporosis; Treatment of moderate to severe vasomotor symptoms associated with menopause
Dosage: TABLET;ORAL
DUAVEE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic